SCHEMBL455445

SCHEMBL455445

C=CCNC(=S)NN=C1Nc2ccccc2C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
GAA P10253 2/20 0.42
TDP1 Q9NUW8 3/20 0.40
KDM4E B2RXH2 2/20 0.40
POLB P06746 1/20 0.40
PTBP1 P26599 1/20 0.40
OPRK1 P41145 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KMT2A Q03164 3/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
PKM P14618 1/20 0.38
LMNA P02545 3/20 0.38
MAPT P10636 3/20 0.38
CYP1A2 P05177 1/20 0.38
THRB P10828 1/20 0.38
CYP2C9 P11712 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL469972 0.83 TDP1 (0.43) ALDH1A1GAATDP1KDM4EPOLB
SCHEMBL458246 0.81 ALDH1A1 (0.49) ALDH1A1GAATDP1KDM4EPOLB
SCHEMBL456020 0.80 LMNA (0.51) ALDH1A1HTTSMN1; SMN2KMT2ACA1
SCHEMBL456344 0.76 KMT2A (0.50) ALDH1A1GAATDP1HTTSMN1; SMN2
SCHEMBL457313 0.76 TDP1 (0.56) ALDH1A1GAATDP1POLBHTT
SCHEMBL2877739 0.76 MAPT (0.51) ALDH1A1GAATDP1KDM4ERAB9A
SCHEMBL2877863 0.76 ALDH1A1 (0.46) ALDH1A1GAAPOLBHTTRAB9A
SCHEMBL455238 0.75 RAB9A (0.44) ALDH1A1GAATDP1POLBRAB9A
SCHEMBL456579 0.74 ALDH1A1 (0.51) ALDH1A1GAATDP1POLBHTT
SCHEMBL455312 0.73 MAPT (0.42) ALDH1A1GAATDP1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2240175-B1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY US GOV HEALTH & HUMAN SERV (US) 2013-01-02 EP disclosed
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
EP-2240175-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) 2010-10-20 EP disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY ABCC1, ABCB1, ABCC2 ALDH1A1 1607/4885GAA 231/4885TDP1 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.